Intellia Therapeutics Inc (NASDAQ:NTLA) outlined its strategic priorities for 2025, emphasizing the acceleration of ...

According to Benzinga Pro, Intellia Therapeutics's peer group average for short interest as a percentage of float is 14.00%, which means the company has more short interest than most of its peers. Did ...

Shares of gene editing companies dropped on Friday as Wall Street reacted to Intellia Therapeutics' (NASDAQ:NTLA) plans to ...

These moves will enable the gene-editing company to focus resources on late-stage programs as it aims to launch a commercial product by 2027, it said.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

BMO Capital lowered the firm’s price target on Intellia Therapeutics (NTLA) to $50 from $70 and keeps an Outperform rating on the shares. The ...

We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...

Intellia Therapeutics stock falls after the company announces key milestones for 2025. It plans to reduce the current workforce by 27%.

Intellia Therapeutics Inc. is shedding employees and paring down its pipeline as it transforms from a late-stage development ...

Intellia Therapeutics, a US gene editing company developing CRISPR-based therapies, announced late Thursday its strategic ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Despite the market's response to the reorganization and workforce reduction, Intellia ended the fourth quarter of 2024 with a strong cash position of approximately $862 million. This financial ...